Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B32cd1a06a2bb66adf8a854f7031cfea1> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B32cd1a06a2bb66adf8a854f7031cfea1 NCIT_P378 "NCI" @default.
- B32cd1a06a2bb66adf8a854f7031cfea1 type Axiom @default.
- B32cd1a06a2bb66adf8a854f7031cfea1 annotatedProperty IAO_0000115 @default.
- B32cd1a06a2bb66adf8a854f7031cfea1 annotatedSource NCIT_C133543 @default.
- B32cd1a06a2bb66adf8a854f7031cfea1 annotatedTarget "A humanized monoclonal immunoglobulin G1 anti-P-selectin antibody with vaso-protective and anti-vaso-occlusive properties. Upon administration, crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand-1 (PSGL-1; SELPLG) on neutrophils and monocytes. P-selectin, a glycoprotein that functions as a cell adhesion molecule (CAM), translocates to the surface of activated endothelial cells and platelets, upon stimulation, where it binds to its ligand and mediates the rolling of platelets and neutrophils on activated endothelial cells. Therefore, blockade of p-selectin may inhibit platelet aggregation, maintain blood flow and minimize sickle cell-related pain crises (SCPC)." @default.